We use our strong scientific knowledge, coupled with our clear understanding of the commercial realities of typically complex, national healthcare systems to generate actionable insights and recommendations for businesses.
Our consulting team
Gareth Elliott
As a Partner at PMSI, Gareth leads our Pharma & Healthcare practice, with deep sector expertise developed over more than a decade of commercial due diligence advisory. Gareth holds a Master’s in Chemistry from the University of Oxford, specialising in drug discovery. Gareth has worked on many transactions in the pharma services space alongside the supporting technology and infrastructure required to develop new medicines. He has worked extensively with some of the UK’s largest and most innovative healthcare providers to support their value propositions and further improve the UK’s healthcare ecosystem.
Alix Day
Alix is the Associate Director in our Pharma & Healthcare practice, with a particular focus on consumer and clinic-based healthcare. Prior to PMSI, Alix worked at CIL advising on the UK, European and US mid-market as well as in operational roles for a number of well known high street retailers, including John Lewis. Through her broad experience, she combines a strategic approach with practical, actionable insight.
When not at work, you’ll find Alix down the gym, at the latest exhibition or planning her next trip to Italy. Alix holds BA in English Literature and Management from the University of Cambridge.
Companies we worked with
How we’ve helped
Vita is a leading £100m+ provider of MSK and mental health services to the NHS, corporates, insurers and B2C.
Acquirer / Investor
Spire Healthcare (publicly listed)
Deal type
VCDD
Deal value
£74m (4.5x investment return)
PMSI value-add
PMSI firstly provided vendor support to refine Vita’s growth strategy (equity story), prior to full VCDD across NHS, Corporate and B2C markets. The acquirer, Spire, then asked PMSI to further advise them on operational synergies with Vita. As a result, Vita was successfully sold with a 4.5x return for shareholders
Latest insights
See what’s shaping the sector through our most recent insights, case studies, and commentary.